A citation-based method for searching scientific literature

Zoe A Efstathiadou, Charalambos Tsentidis, Alexandra Bargiota, Vasiliki Daraki, Kalliopi Kotsa, Georgia Ntali, Labrini Papanastasiou, Stelios Tigas, Konstantinos Toulis, Kalliopi Pazaitou-Panayiotou, Maria Alevizaki. Eur Thyroid J 2021
Times Cited: 5







List of co-cited articles
16 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Lori J Wirth, Eric Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen Lorch, Francis Worden, Marcia Brose, Jyoti Patel, Sophie Leboulleux,[...]. N Engl J Med 2020
171
60

Cabozantinib in progressive medullary thyroid cancer.
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, Patrick Schöffski, Marcia S Brose, Manisha H Shah, Lisa Licitra, Barbara Jarzab, Viktor Medvedev, Michael C Kreissl,[...]. J Clin Oncol 2013
658
60

Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.
Samuel A Wells, Sylvia L Asa, Henning Dralle, Rossella Elisei, Douglas B Evans, Robert F Gagel, Nancy Lee, Andreas Machens, Jeffrey F Moley, Furio Pacini,[...]. Thyroid 2015
929
60

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli,[...]. J Clin Oncol 2012
849
60

Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Viktoria F Koehler, Pia Adam, Karin Frank-Raue, Friedhelm Raue, Elke Berg, Eva Hoster, Stephanie Allelein, Matthias Schott, Matthias Kroiss, Christine Spitzweg. Thyroid 2021
17
60

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
S Filetti, C Durante, D Hartl, S Leboulleux, L D Locati, K Newbold, M G Papotti, A Berruti. Ann Oncol 2019
211
60

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.
M Schlumberger, R Elisei, S Müller, P Schöffski, M Brose, M Shah, L Licitra, J Krajewska, M C Kreissl, B Niederle,[...]. Ann Oncol 2017
81
60

Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls.
Carolien M Beukhof, Tessa Brabander, Francien H van Nederveen, Marie-Louise F van Velthuysen, Yolanda B de Rijke, Leo J Hofland, Gaston J H Franssen, Lideke A C Fröberg, Boen L R Kam, W Edward Visser,[...]. BMC Cancer 2019
22
40

Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial.
Dapeng Li, Yihebali Chi, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng,[...]. Clin Cancer Res 2021
12
40

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.
Martin Schlumberger, Barbara Jarzab, Maria E Cabanillas, Bruce Robinson, Furio Pacini, Douglas W Ball, Judith McCaffrey, Kate Newbold, Roger Allison, Renato G Martins,[...]. Clin Cancer Res 2016
134
40

FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions.
Diana Bradford, Erin Larkins, Sirisha L Mushti, Lisa Rodriguez, Amy M Skinner, Whitney S Helms, Lauren S L Price, Jeanne Fourie Zirkelbach, Yangbing Li, Jiang Liu,[...]. Clin Cancer Res 2021
23
40

Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times.
Anne Laure Giraudet, Abir Al Ghulzan, Anne Aupérin, Sophie Leboulleux, Ahmed Chehboun, Frédéric Troalen, Clarisse Dromain, Jean Lumbroso, Eric Baudin, Martin Schlumberger. Eur J Endocrinol 2008
144
40

Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.
Julien Hadoux, Martin Schlumberger. Best Pract Res Clin Endocrinol Metab 2017
22
40

Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial.
Fabienne Iten, Beat Müller, Christian Schindler, Christoph Rochlitz, Daniel Oertli, Helmut R Mäcke, Jan Müller-Brand, Martin A Walter. Clin Cancer Res 2007
95
40

Peptide Receptor Radionuclide Therapy (PRRT) of Medullary and Nonmedullary Thyroid Cancer Using Radiolabeled Somatostatin Analogues.
Ali Salavati, Ameya Puranik, Harshad R Kulkarni, Hendra Budiawan, Richard P Baum. Semin Nucl Med 2016
38
40

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R Haugen, Erik K Alexander, Keith C Bible, Gerard M Doherty, Susan J Mandel, Yuri E Nikiforov, Furio Pacini, Gregory W Randolph, Anna M Sawka, Martin Schlumberger,[...]. Thyroid 2016
40

A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.
Alain Ravaud, Christelle de la Fouchardière, Philippe Caron, Adelaïde Doussau, Christine Do Cao, Julien Asselineau, Patrice Rodien, Damien Pouessel, Patricia Nicolli-Sire, Marc Klein,[...]. Eur J Cancer 2017
63
20

Response to initial therapy predicts clinical outcomes in medullary thyroid cancer.
Susan C Lindsey, Ian Ganly, Frank Palmer, R Michael Tuttle. Thyroid 2015
38
20

Age-Period-Cohort Analysis of Thyroid Cancer Incidence in Korea.
Chang-Mo Oh, Kyu-Won Jung, Young-Joo Won, Aesun Shin, Hyun-Joo Kong, Jin-Soo Lee. Cancer Res Treat 2015
44
20

Pralsetinib: First Approval.
Anthony Markham. Drugs 2020
31
20

Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group.
Jean-François Chatal, Loïc Campion, Françoise Kraeber-Bodéré, Stephane Bardet, Jean-Philippe Vuillez, Bernard Charbonnel, Vincent Rohmer, Chien-Hsing Chang, Robert M Sharkey, David M Goldenberg,[...]. J Clin Oncol 2006
132
20

Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience.
Mijin Kim, Jee Hee Yoon, Jonghwa Ahn, Min Ji Jeon, Hee Kyung Kim, Dong Jun Lim, Ho-Cheol Kang, In Joo Kim, Young Kee Shong, Tae Yong Kim,[...]. Endocrinol Metab (Seoul) 2020
6
20

Medullary thyroid carcinoma: importance of serial serum calcitonin measurement.
A V Stepanas, N A Samaan, C S Hill, R C Hickey. Cancer 1979
96
20

Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
Françoise Kraeber-Bodéré, Caroline Rousseau, Caroline Bodet-Milin, Ludovic Ferrer, Alain Faivre-Chauvet, Loïc Campion, Jean-Philippe Vuillez, Anne Devillers, Chien-Hsing Chang, David M Goldenberg,[...]. J Nucl Med 2006
74
20

Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
Valentina De Falco, Preziosa Buonocore, Magesh Muthu, Liborio Torregrossa, Fulvio Basolo, Marc Billaud, Joseph M Gozgit, Francesca Carlomagno, Massimo Santoro. J Clin Endocrinol Metab 2013
65
20


New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations.
Cristina Romei, Francesca Casella, Alessia Tacito, Valeria Bottici, Laura Valerio, David Viola, Virginia Cappagli, Antonio Matrone, Raffaele Ciampi, Paolo Piaggi,[...]. J Med Genet 2016
32
20

Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial.
Michael C Kreissl, Lars Bastholt, Rossella Elisei, Robert Haddad, Ole Hauch, Barbara Jarząb, Bruce Robinson, Raffaella Colzani, Meredith Foster, Richard Weiss,[...]. J Clin Oncol 2020
15
20

Biomarker-based risk stratification for previously untreated medullary thyroid cancer.
Andreas Machens, Henning Dralle. J Clin Endocrinol Metab 2010
153
20

Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer.
Helton Estrela Ramos, Fabio Hecht, Amandine Berdelou, Isabelle Borget, Sophie Leboulleux, Eric Baudin, Martin Schlumberger. Endocrine 2021
8
20

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha Shah, Ronnie Shapira-Frommer, Kazuhiko Nakagawa, Hyun Cheol Chung, Hedy L Kindler, Jose A Lopez-Martin, Wilson H Miller,[...]. Lancet Oncol 2020
540
20

Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy.
Hyemi Kwon, Won Gu Kim, Min Ji Jeon, Dong Eun Song, Yu-Mi Lee, Tae-Yon Sung, Ki-Wook Chung, Jong Ho Yoon, Suck Joon Hong, Jung Hwan Baek,[...]. Endocrine 2016
14
20

Dynamic risk stratification in the follow-up of thyroid cancer: what is still to be discovered in 2017?
Jolanta Krajewska, Ewa Chmielik, Barbara Jarząb. Endocr Relat Cancer 2017
24
20

Rethinking the Current American Joint Committee on Cancer TNM Staging System for Medullary Thyroid Cancer.
Mohamed Abdelgadir Adam, Samantha Thomas, Sanziana A Roman, Terry Hyslop, Julie A Sosa. JAMA Surg 2017
35
20

Updates on the Management of Thyroid Cancer.
Katherine A Araque, Sriram Gubbi, Joanna Klubo-Gwiezdzinska. Horm Metab Res 2020
27
20

Dendritic cell vaccination in medullary thyroid carcinoma.
Anton Stift, Monika Sachet, Rubina Yagubian, Clemens Bittermann, Peter Dubsky, Christine Brostjan, Roswitha Pfragner, Bruno Niederle, Raimund Jakesz, Michael Gnant,[...]. Clin Cancer Res 2004
49
20

Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma.
C Papewalis, M Wuttke, B Jacobs, J Domberg, H Willenberg, T Baehring, K Cupisti, A Raffel, L Chao, R Fenk,[...]. Horm Metab Res 2008
30
20

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
20


Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
Kathryn Tran, Sairah Khan, Mina Taghizadehasl, Fausto Palazzo, Andrea Frilling, Jeannie F Todd, Adil Al-Nahhas. Hell J Nucl Med 2015
21
20

Medullary thyroid carcinoma.
F Pacini, M G Castagna, C Cipri, M Schlumberger. Clin Oncol (R Coll Radiol) 2010
132
20

Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer.
F Orlandi, P Caraci, A Berruti, B Puligheddu, G Pivano, L Dogliotti, A Angeli. Ann Oncol 1994
66
20

Medullary Thyroid Cancer Patient's Assessment of Quality of Life Tools: Results from the QaLM Study.
Laura Moss, Catrin Cox, Jonathan Wadsley, Kate Newbold, Mark W J Strachan, Maralyn Druce, Neil Tolley, Kathryn Graham, Sarah Jefferies, Lydia Fresco,[...]. Eur Thyroid J 2021
1
100

Quality of life in thyroid cancer patients: a literature review.
Elena Bãrbuş, Claudiu Peştean, Maria Iulia Larg, Doina Piciu. Clujul Med 2017
22
20

Evaluation of the quality of life in patients followed for differentiated cancer of the thyroid.
Nassim Essabah Haraj, Hicham Bouri, Siham El Aziz, Samira Nani, Noureddine Habti, Asma Chadli. Ann Endocrinol (Paris) 2019
6
20

Mindfulness-based stress reduction in patients with differentiated thyroid cancer receiving radioactive iodine therapy: a randomized controlled trial.
Tianji Liu, Wenqi Zhang, Shuai Xiao, Lei Xu, Qiang Wen, Lin Bai, Qingjie Ma, Bin Ji. Cancer Manag Res 2019
9
20

The most common factors influencing on quality of life of thyroid cancer patients after thyroid hormone withdrawal.
Mateja Rubic, Sanja Kusacic Kuna, Vanja Tesic, Tatjana Samardzic, Marija Despot, Drazen Huic. Psychiatr Danub 2014
8
20

The EORTC module for quality of life in patients with thyroid cancer: phase III.
Susanne Singer, Susan Jordan, Laura D Locati, Monica Pinto, Iwona M Tomaszewska, Cláudia Araújo, Eva Hammerlid, E Vidhubala, Olga Husson, Naomi Kiyota,[...]. Endocr Relat Cancer 2017
16
20

Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.
D Taïeb, F Sebag, M Cherenko, K Baumstarck-Barrau, C Fortanier, B Farman-Ara, C De Micco, J Vaillant, S Thomas, B Conte-Devolx,[...]. Clin Endocrinol (Oxf) 2009
70
20

High prevalence of self-reported shoulder complaints after thyroid carcinoma surgery.
Sean H P P Roerink, Lien Coolen, Maria E Schenning, Olga Husson, Jan W A Smit, Henri A Marres, Johannes H W de Wilt, Romana T Netea-Maier. Head Neck 2017
7
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.